User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 4 results.
    • Speech
    Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
    Raghav, Kanwal Pratap Singh Yoshino, Takayuki Guimbaud, Rosine Chau, Ian Van den Eynde, Marc[UCL] Maurel, Joan Tie, Jeanne Kim, Tae Won Yeh, Kun-Huei Barrios, Daniel Kobayashi, Kojiro Bako, Emarjola Aregay, Mehreteab Meinhardt, Gerold Siena, Salvatore (2021) 2021 ASCO Annual Meeting I —
    • Speech
    Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
    Raghav, Kanwal Pratap Singh Yoshino, Takayuki Guimbaud, Rosine Chau, Ian Van den Eynde, Marc[UCL] Maurel, Joan Tie, Jeanne Kim, Tae Won Yeh, Kun-Huei Barrios, Daniel Kobayashi, Kojiro Bako, Emarjola Aregay, Mehreteab Meinhardt, Gerold Siena, Salvatore (2022) 2022 ASCO Gastrointestinal Cancers Symposium —
    • Journal article
    Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Fuchs, Charles S Shitara, Kohei Di Bartolomeo, Maria Lonardi, Sara Al-Batran, Salah-Eddin Van Cutsem, Eric Ilson, David H Alsina, Maria Chau, Ian Lacy, Jill Ducreux, Michel Mendez, Guillermo Ariel Alavez, Alejandro Molina Takahari, Daisuke Mansoor, Wasat Enzinger, Peter C Gorbounova, Vera Wainberg, Zev A Hegewisch-Becker, Susanna Ferry, David Lin, Ji Carlesi, Roberto Das, Mayukh Shah, Manish A RAINFALL Study Group Van den Eynde, Marc[UCL] (2019) The Lancet. Oncology — , p. [1-16] (2019)
    • Journal article
    Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu, Andrew X Park, Joon Oh Ryoo, Baek-Yeol Yen, Chia-Jui Poon, Ronnie Pastorelli, Davide Blanc, Jean-Frederic Chung, Hyun Cheol Baron, Ari D Pfiffer, Tulio Eduardo Flesch Okusaka, Takuji Kubackova, Katerina Trojan, Jorg Sastre, Javier Chau, Ian Chang, Shao-Chun Abada, Paolo B Yang, Ling Schwartz, Jonathan D Kudo, Masatoshi Borbath, Ivan[UCL] (2015) The Lancet Oncology — Vol. 16, no. 7, p. 859-870 (2015)